alexa Complementary and Alternative Medicines (CAM) and its Role in Thalassemia Treatment | Open Access Journals
ISSN: 2327-5162
Alternative & Integrative Medicine
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Complementary and Alternative Medicines (CAM) and its Role in Thalassemia Treatment

Wan Ismahanisa1, Mohamed Azmi Hassali2, Ramli Mohd Yunus3 and Maryam Farooqui4*

1Faculty of Health Science, Universiti Teknologi MARA (UITM) Penang, Malaysia

2Discipline of Social and Administrative Pharmacy, Universi Sains Malaysia, Penang, Malaysia

3Thalassemia International Board Member, Malaysia

4Faculty of Pharmacy, Universiti Teknologi MARA (UITM) Penang, Malaysia

*Corresponding Author:
Maryam Farooqui
Faculty of Pharmacy, University of Technology MARA, Malaysia
Tel: 06-04-5623561
E-mail: maryamfarooqui.uitm@gmail.com

Received date November 30, 2013; Accepted date November 30, 2013; Published date December 02, 2013

Citation: Ismahanisa W, Hassali MA, Yunus RM, Farooqui M (2013) Complementary and Alternative Medicines (CAM) and its Role in Thalassemia Treatment. Altern Integr Med 3:e111. doi:10.4172/2327-5162.1000e111

Copyright: © 2013 Ismahanisa W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Alternative & Integrative Medicine

Predominantly Complementary and Alternative Medicine (CAM) is considered as health care practices that differ from the biomedicine [1]. Worldwide the estimated adult general population for CAM use varies from as low as 32% [2] to as high as 80% [3].

CAM use is common among patients with chronic diseases such as arthritis, cancer [4], Acquired Immunodeficiency Syndrome (AIDS) [4]. Thalassemia is a chronic life long illness which requires biomedicine treatment for the first few months after birth and persisted until death. The World Health Organization (WHO) listed the hemoglobinopathies disorder such as thalassemia as one of urgent health problems which has considerable impact on health care system. In addition WHO concerns, because due to high cost of treatment for thalassemia, its increasing prevalence, morbidity, mortality rates within few years of life in people left untreated [5]. The differences in CAM estimates have been attributed to time or place but CAM estimates for apparently similar to the population that take around the same time. For example estimated American children with cancer from 8.7% [6] to 65% [7] use CAM as a treatment. The reason the people with the serious illness use CAM in the situation of highly sophisticated biomedicine has proven that difficult to determine.

Even though CAM treatment can reduce the morbidity and the mortality but it may have potentials of unnecessary interactions with the prescribed biomedicines. For example the CAM therapies such as herbs and vitamin can mask or distort the biomedical treatments and for this reason the possible effect of combining biomedical and CAM might give harmful effects or may lead to inaccurate biochemical results. Such concerns are probable because people with chronic disease have been found always use CAM therapies at the same time with biomedicine.

Thalassemia is a chronic condition that requires regular blood transfusion. Whilst, most research that related to thalassemia was limited to biomedical issues (such people might also use CAM as their treatment. A comprehensive search of the literature review yielded that only one article that specifically related to CAM and thalassemia. This article detailed that the children use of CAM and majority of the parents (36.1%) stated that they used CAM to ensure their children’s health and protect them against disease [8]. Moreover the study of the reasons for CAM used and its disclosure to treating practitioners has never been undertaken with people that who depend on the biomedicine treatment from cradle to grave. Thus the exploration of the reasons of CAM use and disclosure to amongst people with lifelong condition like Thalassemia is deemed necessary. Therefore the most studies that shows the participants that using CAM because to avoid or relief the musculoskeletal problems and distressing and painful conditions [9] which suggest that CAM use was for a treatment not on lifestyle practice. For example poorer physical health associated with chronic illnesses with accounted 60% of CAM use and 35% of such use for pain.

It is important to study of thalassemia because there are intensively biomedical treated for the duration of their life, which means the person that use of CAM might be jeopardising their health.

The review of the existing literature on CAM disclosure suggested that CAM disclosure estimates were disproportionate with estimates for CAM use in thalassemia [10] whilst the research into illness like thalassemia is extensive and there is no knowledge to concurrent related to CAM and biochemical use amongst this population. Hence this issue highlight the CAM and the importance on the frequency of use and the reasons why people with thalassemia use CAM despite their lifetime and need of the biomedical treatment.

The enduring nature of chronic illness such thalassemia, places are demands on people who have such illness. It includes the need for them to follow the invasive of the treatment and the medication which can emphasize health’s problem. The thalassemia patient is in need of the biomedical treatment from the infant until death and it is most severe form of the haemolytic of the congenital haemolytic anaemia. Hence the thalassemia major can be categorized as a severe and chronic disease, requiring long life treatment. This study is the first to explore the issues that related to the use and disclosure of CAM use and disclosure by the chronically ill by the exploring the discrepancy of the rise of CAM use and the limited of the disclosure to the biomedicine practitioners.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11831
  • [From(publication date):
    February-2014 - Oct 24, 2017]
  • Breakdown by view type
  • HTML page views : 8011
  • PDF downloads :3820
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords